Angioedema after intravitreal bevacizumab injection.
A 47-year-old male with a history of diabetes mellitus type 2 exhibited with decreased vision in both eyes. The diagnosis of cystoid macular edema (CME) was made and it was decided to administer bilateral intravitreal bevacizumab (Avastin) injections. After intravitreal bevacizumab injection (1.25 mg/0.05 cc) to the right eye the patient had angioedema and conjunctival chemosis in the right eye which resolved in 48 h. One month later the left eye received intravitreal bevacizumab injection under the same conditions. Thirty minutes after the injection angioedema and conjunctival chemosis occurred in the left eye in which the signs and symptoms improved in 48 h. This report is the first one which describes angioedema after intravitreal bevacizumab injection. Care should be taken against the systemic hypersensitivity reactions when planned to receive intravitreal bevacizumab injection.
1st Ophthalmology Department, Ankara Atatürk Research and Training Hospital, Bilkent, Ankara, Turkey.
Yasin
Y
Toklu
Ozge
O
Sarac
Sule
S
Berk
Saban
S
Simsek
D000799:Angioedema / Q000139:chemically induced*; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000068258:Bevacizumab; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D003930:Diabetic Retinopathy / Q000188:drug therapy; D004342:Drug Hypersensitivity / Q000209:etiology*; D005128:Eye Diseases / Q000139:chemically induced; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000139:chemically induced*; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab